Zhejiang Jingxin Pharmaceutical 京新药业
11 significant filings since 1 Jun 2026: 9 on buyback, 1 on dividend and 1 on management change. The latest, on 2 Sep 2026: 关于股份回购进展公告. 1 unverified report logged, the latest on 26 Jun 2026.
自 1 Jun 2026 起有 11 份重大公告：buyback 9 份、dividend 1 份、management change 1 份。最新一份（2 Sep 2026）：关于股份回购进展公告。记录了 1 条未经核实的报道，最新一条见于 26 Jun 2026。
Price History 价格走势
1,250 trading days 个交易日 · High 最高 ¥21.06 · Low 最低 ¥6.78The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 15 Jan 2024 | 山西证券 | 魏赟 | Outperform 增持 | ▲ | Buy 买入 |
| 28 Aug 2019 | 东兴证券 | 胡博新,许睿 | Buy 买入 | ▼ | Outperform 增持 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 西南证券 | 杜向阳 | Buy 买入 | 1 Sep 2026 | 1 | — |
| 开源证券 | 余汝意,刘艺 | Buy 买入 | 28 Apr 2026 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 2 reports. 每行为该券商近十二个月的最新研报；2 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。